Category: Interpretational.com

Medivation and Astellas Announce The Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naïve Patients With Advanced Prostate Cancer

81% Reduction in the Risk of Radiographic Progression or Death, Hazard Ratio=0.19 (p Medivation to Hold Conference Call at 8:30 a.m. Eastern Time Today San Francisco, CA and Tokyo – October 22, 2013 – Medivation, Inc. (Nasdaq: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the Independent Data Monitoring Committee (IDMC) has informed the companies of positive results...

READ MORE Medivation and Astellas Announce The Phase 3 PREVAIL Trial of Enzalutamide Meets Both Co-Primary Endpoints of Overall Survival and Radiographic Progression-Free Survival in Chemotherapy-Naïve Patients With Advanced Prostate Cancer

Consumer Confidence stalls at zero

Do Brexit jitters explain 18-point fall since March 2015 in sentiment over future prospects for general economy? GfK’s long-running Consumer Confidence Index remained at zero in March.  Two of the measures used to calculate the Index saw decreases this month, with one measure showing an increase and the remaining two measures staying the same. Joe Staton, Head of Market Dynamics...

READ MORE Consumer Confidence stalls at zero

Mapping Giants Merge To Create 10mm Accurate Heavyweight

Maps are essential for any strategy. For autonomous cars, maps are the strategy. Away from the headlines, a global war is waged for interpretational jurisdiction in the mapping business:  Those who define the standards will reap the rewards.  At first glance, a relatively unknown Japanese company bought a little-known American outfit today.  Once you look at the bigtime backers of...

READ MORE Mapping Giants Merge To Create 10mm Accurate Heavyweight

Generated by Feedzy